3 ratings / 2.67 average

Pharmacogenetics of Colorectal Cancer and Individualized Management

Alexios S Strimpakos MD, MRCP1, Muhammad W Saif MD, MBBS2, and Kostas N Syrigos MD, PhD1,2

Colorectal cancer (CRC) is the third most common cancer in both men and women, and the third most common cause of cancer-related death in the UK and the US [1]. Men have a lifetime probability of developing CRC of approximately 6%, and women have a lifetime probability of approximately 5% [1]. Early diagnosis of CRC relies on screening, with colonoscopy and fecal occult blood testing being the most commonly used screening methods. When CRC is diagnosed after symptoms have occurred, the disease may be more advanced, and cure cannot be guaranteed despite recent significant advances in treatment.

Return to top

RELATED ARTICLES

Optimal Management for Rectal Cancer
ALEXANDER G HERIOT AND CRAIG LYNCH
CML Gastroenterology
Pharmacogenetics of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis: An Update
Hamid Bashir, MD, and Prabha Ranganathan, MD
International Journal of Advances in Rheumatology
New Developments in the Pharmacogenetics of Psoriasis: 
HLA-Cw6 as a Marker for the Treatment of Psoriasis with Biological Therapies
Antonio Costanzo, MD, Giulia Spallone, MD, Marina Talamonti, MD, 
Elisabetta Botti, MD, and Sergio Chimenti, MD
Advances in Psoriasis and Inflammatory Skin Diseases
Managing Low-Grade Dysplasia
Aelaf D Worku, MD, and Thomas A Ullman, MD
Inflammatory Bowel Disease Monitor
Epidemiology and Outcomes
Inflammatory Bowel Disease Monitor

LATEST ARTICLES

Our most popular articles